Market Closed -
Nasdaq
04:00:00 2024-05-02 pm EDT
|
5-day change
|
1st Jan Change
|
23.86
USD
|
-0.62%
|
|
-2.37%
|
-13.99%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,213
|
3,175
|
3,761
|
4,293
|
4,629
|
4,037
|
-
|
-
|
Enterprise Value (EV)
1 |
2,956
|
2,790
|
3,291
|
3,847
|
4,107
|
3,247
|
3,007
|
2,858
|
P/E ratio
|
-16.3
x
|
-28.5
x
|
-77.5
x
|
-26.9
x
|
13.2
x
|
12.3
x
|
12.2
x
|
11.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.74
x
|
3.06
x
|
3.2
x
|
3.86
x
|
2.78
x
|
2.68
x
|
2.68
x
|
2.57
x
|
EV / Revenue
|
2.52
x
|
2.69
x
|
2.8
x
|
3.46
x
|
2.47
x
|
2.16
x
|
1.99
x
|
1.82
x
|
EV / EBITDA
|
-21.9
x
|
-38.2
x
|
66.7
x
|
-59.7
x
|
8.44
x
|
6.67
x
|
6.19
x
|
4.94
x
|
EV / FCF
|
-157
x
|
68.7
x
|
44.7
x
|
-224
x
|
11.6
x
|
7.92
x
|
7.43
x
|
5.73
x
|
FCF Yield
|
-0.64%
|
1.46%
|
2.24%
|
-0.45%
|
8.6%
|
12.6%
|
13.5%
|
17.4%
|
Price to Book
|
2.97
x
|
2.97
x
|
3.36
x
|
4.11
x
|
3.85
x
|
2.65
x
|
2.07
x
|
1.74
x
|
Nbr of stocks (in thousands)
|
157,522
|
159,150
|
161,705
|
164,312
|
166,881
|
169,184
|
-
|
-
|
Reference price
2 |
20.40
|
19.95
|
23.26
|
26.13
|
27.74
|
23.86
|
23.86
|
23.86
|
Announcement Date
|
2/13/20
|
2/11/21
|
2/16/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,171
|
1,039
|
1,174
|
1,112
|
1,663
|
1,503
|
1,507
|
1,572
|
EBITDA
1 |
-135.1
|
-72.98
|
49.37
|
-64.4
|
486.7
|
486.5
|
485.4
|
578.1
|
EBIT
1 |
-175.5
|
-112.4
|
-29.29
|
-142.3
|
414.1
|
425.1
|
448.1
|
514.6
|
Operating Margin
|
-14.99%
|
-10.82%
|
-2.5%
|
-12.8%
|
24.9%
|
28.28%
|
29.73%
|
32.73%
|
Earnings before Tax (EBT)
1 |
-197.1
|
-96.54
|
-39.31
|
-167.3
|
421.5
|
416.2
|
459.3
|
514.2
|
Net income
1 |
-196.6
|
-110.9
|
-48.17
|
-158.3
|
355.8
|
336.1
|
351.7
|
387.6
|
Net margin
|
-16.79%
|
-10.67%
|
-4.1%
|
-14.24%
|
21.39%
|
22.36%
|
23.33%
|
24.65%
|
EPS
2 |
-1.250
|
-0.7000
|
-0.3000
|
-0.9700
|
2.100
|
1.935
|
1.951
|
2.055
|
Free Cash Flow
1 |
-18.86
|
40.62
|
73.7
|
-17.21
|
353.3
|
410
|
404.8
|
498.6
|
FCF margin
|
-1.61%
|
3.91%
|
6.28%
|
-1.55%
|
21.24%
|
27.27%
|
26.86%
|
31.72%
|
FCF Conversion (EBITDA)
|
-
|
-
|
149.28%
|
-
|
72.59%
|
84.28%
|
83.41%
|
86.26%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
99.31%
|
121.97%
|
115.11%
|
128.64%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/13/20
|
2/11/21
|
2/16/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
294.1
|
324.5
|
278.5
|
276.2
|
252.4
|
304.7
|
287.6
|
617.4
|
380.9
|
377.5
|
350.4
|
392.6
|
383.5
|
375.1
|
366.7
|
EBITDA
1 |
-10.04
|
23.53
|
-7.388
|
-25.39
|
-51.48
|
-0.907
|
-38.69
|
66.97
|
78.09
|
72.85
|
49.03
|
159.5
|
163
|
159.7
|
-
|
EBIT
1 |
-19.66
|
2.383
|
-26.58
|
-34.46
|
-60.64
|
-20.58
|
-47.49
|
239.2
|
43.85
|
54.63
|
43.31
|
121
|
128.4
|
130.1
|
118.8
|
Operating Margin
|
-6.68%
|
0.73%
|
-9.54%
|
-12.47%
|
-24.03%
|
-6.76%
|
-16.51%
|
38.74%
|
11.51%
|
14.47%
|
12.36%
|
30.81%
|
33.47%
|
34.67%
|
32.4%
|
Earnings before Tax (EBT)
1 |
-26.54
|
0.227
|
-45
|
-33.25
|
-67.37
|
-21.69
|
-47.86
|
239.8
|
47.36
|
58.32
|
46.91
|
104.6
|
136.3
|
143.9
|
134.7
|
Net income
1 |
-28.99
|
0.873
|
-35.9
|
-30.14
|
-63.97
|
-28.25
|
-41.84
|
237.1
|
47.76
|
112.8
|
36.83
|
85.84
|
113.9
|
119.4
|
106.4
|
Net margin
|
-9.86%
|
0.27%
|
-12.89%
|
-10.91%
|
-25.35%
|
-9.27%
|
-14.55%
|
38.4%
|
12.54%
|
29.88%
|
10.51%
|
21.86%
|
29.71%
|
31.83%
|
29.03%
|
EPS
2 |
-0.1800
|
0.0100
|
-0.2200
|
-0.1800
|
-0.3900
|
-0.1700
|
-0.2500
|
1.380
|
0.2800
|
0.6600
|
0.2100
|
0.5250
|
0.5834
|
0.6800
|
0.5800
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/27/21
|
2/16/22
|
4/27/22
|
7/27/22
|
11/2/22
|
2/16/23
|
4/26/23
|
7/26/23
|
10/25/23
|
2/15/24
|
5/1/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
258
|
385
|
470
|
447
|
523
|
790
|
1,030
|
1,179
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-18.9
|
40.6
|
73.7
|
-17.2
|
353
|
410
|
405
|
499
|
ROE (net income / shareholders' equity)
|
9.94%
|
6.38%
|
11.8%
|
5.37%
|
21.7%
|
30.5%
|
22.4%
|
19.6%
|
ROA (Net income/ Total Assets)
|
6.18%
|
3.66%
|
6.5%
|
2.9%
|
11.9%
|
20.2%
|
17.3%
|
14.5%
|
Assets
1 |
-3,181
|
-3,032
|
-741.4
|
-5,455
|
2,993
|
1,666
|
2,028
|
2,669
|
Book Value Per Share
2 |
6.880
|
6.720
|
6.910
|
6.350
|
7.200
|
9.010
|
11.50
|
13.70
|
Cash Flow per Share
2 |
0.4600
|
0.5200
|
0.6300
|
0.1300
|
2.360
|
3.520
|
2.740
|
-
|
Capex
1 |
90.9
|
42.2
|
28
|
38.3
|
48
|
40.5
|
38.7
|
38.2
|
Capex / Sales
|
7.77%
|
4.06%
|
2.39%
|
3.44%
|
2.89%
|
2.69%
|
2.57%
|
2.43%
|
Announcement Date
|
2/13/20
|
2/11/21
|
2/16/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Last Close Price
23.86
USD Average target price
33.82
USD Spread / Average Target +41.74% Consensus |
1st Jan change
|
Capi.
|
---|
| -13.99% | 4.04B | | +26.28% | 48.09B | | -3.99% | 40.43B | | +46.85% | 40.62B | | -6.20% | 28.36B | | +6.36% | 24.89B | | -21.47% | 19.01B | | +27.58% | 12.09B | | -2.75% | 11.8B | | -2.02% | 11.88B |
Other Biotechnology & Medical Research
|